Brand-name chemotherapy is often incredibly expensive, in excess of $100,000 per patient. Sometimes there are excellent generic alternatives, but many oncologists are hesitant to prescribe generics because such prescriptions cost them money. For many medicines, you see, oncologists receive a 6% markup, meaning when they infuse a patient with a $10,000 monthly course of chemotherapy,…
Nine to twelve years. That’s about how long most drug companies have to make serious money on new products before their patent protection ends. Then, generic companies enter the fray and prices, typically, plummet. Yet, two decades after coming to market, Herceptin (a drug used to treat breast and stomach cancer) was still priced at…
A recent economic analysis concluded that patients with metastatic cancer value their treatments significantly more than regulators recognize, with many expensive new therapies looking like veritable bargains to most patients.
read more
My visit to this well-intentioned dermatologist illustrates one of the flaws of this idea of consumer empowerment.
An interesting article by Peter Schwartz in the latest Hastings Center Report on whether patients, facing difficult medical decisions, ought to get precise numbers on the risks and benefits of their alternatives. I contributed a commentary, urging researchers to keep developing better ways to help patients make rational use of the numbers.
Was I right to prescribe an inferior medication to my patient?
read more